Inclusion Criteria:  ≥1 International Classification of Diseases, Clinical Modification-9/10 CM (ICD- 9/10) code for wet AMD in 2019 ≥1 Healthcare Common Procedure Coding System (HCPCS) code (J code) or National Drug Code (NDC) code for treatment with an anti-VEGF agent (excluding brolucizumab) in 2019 ≥18 years old in 2019 ≥2 wet AMD-related office visits in 2019  Exclusion Criteria:  Patient eyes that received >1 type of anti-VEGF treatment on the same date Patient eyes that did not have laterality any time during 2018-2019 Treatment with brolucizumab during 2019